骨髄異形成症候群の世界市場レポート 2025年

骨髄異形成症候群市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR10.0％で41億7,000万米ドルに成長します。予測期間の成長は、高齢化、併用療法の採用、血液学的研究への投資、個別化医療に起因します。予測期間の主な動向には、骨髄異形成症候群の革新的治療、診断ツールや技術の進歩、臨床試験、共同研究などが含まれます。

希少な血液がんの発生率の上昇が、今後数年間の骨髄異形成症候群（MDS）市場の成長を促進すると予測されます。血液悪性腫瘍である血液がんは、集団における発生率が低く、骨髄、リンパ節、その他の血液および免疫系構成要素の細胞から発生します。MDSの治療は、骨髄での血液がんの進行を防ぐため、血球の産生を高め、症状に対処することで状態を管理することに重点を置いています。例えば、米国を拠点とする専門機関である白血病リンパ腫協会は2024年9月、米国では3分に1人が白血病、リンパ腫、骨髄腫と診断されていると報告しました。2024年には、187,740人がこれらのがんと診断され、米国で予想される新規がん患者数2,001,140人の9.4%を占めると推定されています。その結果、血液がんの発生率の増加が骨髄異形成症候群（MDS）市場の拡大を牽引しています。

骨髄移植の増加が予想されることから、骨髄異形成症候群（MDS）市場の今後の成長が予測されます。骨髄移植は、様々な症状を治療するために、損傷または病気の骨髄を健康な幹細胞と置き換える医療処置です。MDSは骨髄不全を特徴とし、これは体細胞的に変化したクローン性造血幹細胞の選択的な開発に起因します。骨髄移植は、異常な幹細胞を健康な幹細胞に置き換えることで、MDSを治療できる可能性があります。例えば、2024年6月、スペインを拠点とする独立調整機関である国立移植機構（ONT）は、2023年にスペイン骨髄ドナー登録に新たに23,686人のドナーが加わり、2022年と比較して8％増加し、造血幹細胞移植の記録は3,717件、人口100万人当たりの移植件数は77.4件に達したと報告しました。したがって、骨髄移植の増加が骨髄異形成症候群市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界骨髄異形成症候群 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の骨髄異形成症候群市場：成長率分析
• 世界の骨髄異形成症候群市場の実績：規模と成長, 2019-2024
• 世界の骨髄異形成症候群市場の予測：規模と成長, 2024-2029, 2034F
• 世界骨髄異形成症候群総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の骨髄異形成症候群市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 骨髄異形成症候群単系統異形成症
• 骨髄異形成症候群多系統異形成症
• 骨髄異形成症候群リング型シデロブラスト
• その他のタイプ
• 世界の骨髄異形成症候群市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• アザシチジン
• レナリドミド
• デシタビン
• デフェラシロクス
• 世界の骨髄異形成症候群市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 支持療法
• 成長因子
• 化学療法
• 幹細胞移植
• その他の治療法
• 世界の骨髄異形成症候群市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射可能
• その他の投与経路
• 世界の骨髄異形成症候群市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界の骨髄異形成症候群市場、単系統異形成を伴う骨髄異形成症候群のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 異形成の種類
• 患者の人口統計
• 世界の骨髄異形成症候群市場、多系統異形成を伴う骨髄異形成症候群のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 異形成の重症度
• 患者の人口統計
• 世界の骨髄異形成症候群市場、リング状シデロブラストによる骨髄異形成症候群のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リング状鉄芽球の割合
• 治療の選択肢
• 世界の骨髄異形成症候群市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特定のタイプ
• 治療の選択肢

第7章 地域別・国別分析

• 世界の骨髄異形成症候群市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の骨髄異形成症候群市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 骨髄異形成症候群市場：競合情勢
• 骨髄異形成症候群市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck & Co.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca Plc.
• Takeda Pharmaceutical Company Limited
• Medtronic Plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Otsuka Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Ltd.
• Jazz Pharmaceuticals
• Dr. Reddy's Laboratories Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 骨髄異形成症候群市場2029：新たな機会を提供する国
• 骨髄異形成症候群市場2029：新たな機会を提供するセグメント
• 骨髄異形成症候群市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Myelodysplastic syndrome (MDS) encompasses a group of conditions characterized by the aberrant development and functioning of bone marrow cells, leading to inefficient production of blood cells. Treatment for myelodysplastic syndrome is aimed at enhancing blood cell counts, alleviating associated symptoms, and retarding the progression of the disease. It's noteworthy that myelodysplastic syndrome (MDS) can evolve into acute myeloid leukemia (AML), a more aggressive form of blood cancer.

Within the spectrum of myelodysplastic syndrome, various subtypes exist, including myelodysplastic syndrome with unilineage dysplasia, myelodysplastic syndrome with multilineage dysplasia, and myelodysplastic syndrome with ring sideroblasts. Myelodysplastic syndrome (MDS) with unilineage dysplasia is a specific classification within the range of MDS conditions. Treatment options for myelodysplastic syndrome encompass a range of drugs such as azacitidine, lenalidomide, decitabine, and deferasirox. Various treatment modalities are employed, including supportive therapy, growth factors, chemotherapy, and stem cell transplantation. These treatments can be administered through multiple routes, including oral, injectable, and others, and are delivered in diverse healthcare settings, such as hospitals, homecare, specialty centers, and more.

The myelodysplastic syndrome market research report is one of a series of new reports from The Business Research Company that provides myelodysplastic syndrome market statistics, including myelodysplastic syndrome industry global market size, regional shares, competitors with a myelodysplastic syndrome market share, detailed myelodysplastic syndrome market segments, market trends and opportunities and any further data you may need to thrive in the myelodysplastic syndrome industry. This myelodysplastic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myelodysplastic syndrome market size has grown rapidly in recent years. It will grow from $2.56 billion in 2024 to $2.85 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing prevalence of myelodysplastic syndrome, growing awareness about myelodysplastic syndrome treatment, rising healthcare spending, government initiatives.

The myelodysplastic syndrome market size is expected to see strong growth in the next few years. It will grow to $4.17 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to aging population, adoption of combination therapies, investment in hematologic research, personalized medicine. Major trends in the forecast period include innovative treatments for myelodysplastic syndrome, advancements in diagnostic tools and techniques, clinical trials, collaborative research.

The rising incidence of rare blood cancers is anticipated to drive the growth of the myelodysplastic syndrome (MDS) market in the coming years. Blood cancers, which are hematologic malignancies, have a low occurrence rate in the population and originate from the cells of the bone marrow, lymph nodes, and other blood and immune system components. MDS treatment focuses on managing the condition by enhancing blood cell production and addressing symptoms to prevent the progression of blood cancer in the bone marrow. For example, in September 2024, the Leukemia and Lymphoma Society, a U.S.-based professional organization, reported that every 3 minutes, one person in the U.S. is diagnosed with leukemia, lymphoma, or myeloma. In 2024, it is estimated that 187,740 individuals will be diagnosed with these cancers, making up 9.4% of the 2,001,140 new cancer cases expected in the U.S. Consequently, the growing incidence of blood cancers is driving the expansion of the myelodysplastic syndrome (MDS) market.

The expected rise in the number of bone marrow transplants is predicted to drive the growth of the myelodysplastic syndrome (MDS) market in the future. A bone marrow transplant is a medical procedure in which damaged or diseased bone marrow is replaced with healthy stem cells to treat various conditions. MDS is characterized by bone marrow failure, which results from the selective development of somatically altered clonal hematopoietic stem cells. Bone marrow transplantation can offer a potential cure for MDS by replacing abnormal stem cells with healthy ones. For example, in June 2024, the National Transplant Organization (ONT), a Spain-based independent coordinating agency, reported that in 2023, Spain added 23,686 new donors to the Spanish Bone Marrow Donor Registry, an 8% increase compared to 2022, and achieved a record 3,717 hematopoietic stem cell transplants, translating to 77.4 transplants per million population. Therefore, the increasing number of bone marrow transplants is driving the growth of the myelodysplastic syndrome market.

Key companies in the myelodysplastic syndrome (MDS) market are developing innovative therapies to enhance their market position. For example, in August 2023, Bristol Myers Squibb, a US-based pharmaceutical company, received FDA approval for Reblozyl (luspatercept-aamt) as a first-line treatment for anemia in ESA-naive adults with low- to intermediate-risk MDS who may require regular RBC transfusions. In the Phase 3 COMMANDS trial, Reblozyl demonstrated superior efficacy in achieving RBC transfusion independence and increasing hemoglobin levels compared to epoetin alfa, providing earlier anemia management for a broader patient population.

In July 2022, GSK plc, a UK-based multinational pharmaceutical and biotechnology company specializing in vaccines and specialty medicines, acquired Sierra Oncology, Inc. for an undisclosed sum. This acquisition strengthens GSK's ability to develop innovative cancer therapies, enabling the company to better address unmet medical needs and enhance its position in the competitive pharmaceutical market, while furthering its commitment to improving patient outcomes in oncology. Sierra Oncology, Inc. is a US-based biopharmaceutical company focused on developing treatments for rare cancers, including myelodysplastic syndromes and primary myelofibrosis.

Major companies operating in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

North America was the largest region in the myelodysplastic syndrome market in 2024. The regions covered in myelodysplastic syndrome (MDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the myelodysplastic syndrome (MDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myelodysplastic syndrome (MDS) market consists of revenues earned by entities by providing experimental therapies, targeted therapies and blood transfusion. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelodysplastic syndrome (MDS) market also consists of sales of erythropoiesis-stimulating agents (ESAs) and immunomodulatory drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myelodysplastic Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myelodysplastic syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myelodysplastic syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myelodysplastic syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia; Myelodysplastic Syndrome With Multilineage Dysplasia; Myelodysplastic Syndrome With Ring Sideroblasts; Other Types
• 2) By Drug: Azacitidine; Lenalidomide; Decitabine; Deferasirox
• 3) By Treatment: Supportive Therapy; Growth Factors; Chemotherapy; Stem Cell Transplant; Other Treatments
• 4) By Route Of Administration: Oral; Injectable; Other Routes Of Administrations
• 5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
• Subsegments:
• 1) By Myelodysplastic Syndrome With Unilineage Dysplasia: Type Of Dysplasia; Patient Demographics
• 2) By Myelodysplastic Syndrome With Multilineage Dysplasia: Severity Of Dysplasia; Patient Demographics
• 3) By Myelodysplastic Syndrome With Ring Sideroblasts: Percentage Of Ring Sideroblasts; Treatment Options
• 4) By Other Types: Specific Types; Treatment Options
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; AbbVie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myelodysplastic Syndrome Market Characteristics

3. Myelodysplastic Syndrome Market Trends And Strategies

4. Myelodysplastic Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Myelodysplastic Syndrome Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myelodysplastic Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myelodysplastic Syndrome Market Growth Rate Analysis
• 5.4. Global Myelodysplastic Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myelodysplastic Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myelodysplastic Syndrome Total Addressable Market (TAM)

6. Myelodysplastic Syndrome Market Segmentation

• 6.1. Global Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Myelodysplastic Syndrome With Unilineage Dysplasia
• Myelodysplastic Syndrome With Multilineage Dysplasia
• Myelodysplastic Syndrome With Ring Sideroblasts
• Other Types
• 6.2. Global Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azacitidine
• Lenalidomide
• Decitabine
• Deferasirox
• 6.3. Global Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supportive Therapy
• Growth Factors
• Chemotherapy
• Stem Cell Transplant
• Other Treatments
• 6.4. Global Myelodysplastic Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Routes Of Administrations
• 6.5. Global Myelodysplastic Syndrome Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centers
• Other End-Users
• 6.6. Global Myelodysplastic Syndrome Market, Sub-Segmentation Of Myelodysplastic Syndrome With Unilineage Dysplasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type Of Dysplasia
• Patient Demographics
• 6.7. Global Myelodysplastic Syndrome Market, Sub-Segmentation Of Myelodysplastic Syndrome With Multilineage Dysplasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Severity Of Dysplasia
• Patient Demographics
• 6.8. Global Myelodysplastic Syndrome Market, Sub-Segmentation Of Myelodysplastic Syndrome With Ring Sideroblasts, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Percentage Of Ring Sideroblasts
• Treatment Options
• 6.9. Global Myelodysplastic Syndrome Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Specific Types
• Treatment Options

7. Myelodysplastic Syndrome Market Regional And Country Analysis

• 7.1. Global Myelodysplastic Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myelodysplastic Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myelodysplastic Syndrome Market

• 8.1. Asia-Pacific Myelodysplastic Syndrome Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myelodysplastic Syndrome Market

• 9.1. China Myelodysplastic Syndrome Market Overview
• 9.2. China Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myelodysplastic Syndrome Market

• 10.1. India Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myelodysplastic Syndrome Market

• 11.1. Japan Myelodysplastic Syndrome Market Overview
• 11.2. Japan Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myelodysplastic Syndrome Market

• 12.1. Australia Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myelodysplastic Syndrome Market

• 13.1. Indonesia Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myelodysplastic Syndrome Market

• 14.1. South Korea Myelodysplastic Syndrome Market Overview
• 14.2. South Korea Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myelodysplastic Syndrome Market

• 15.1. Western Europe Myelodysplastic Syndrome Market Overview
• 15.2. Western Europe Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myelodysplastic Syndrome Market

• 16.1. UK Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myelodysplastic Syndrome Market

• 17.1. Germany Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myelodysplastic Syndrome Market

• 18.1. France Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myelodysplastic Syndrome Market

• 19.1. Italy Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myelodysplastic Syndrome Market

• 20.1. Spain Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myelodysplastic Syndrome Market

• 21.1. Eastern Europe Myelodysplastic Syndrome Market Overview
• 21.2. Eastern Europe Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myelodysplastic Syndrome Market

• 22.1. Russia Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myelodysplastic Syndrome Market

• 23.1. North America Myelodysplastic Syndrome Market Overview
• 23.2. North America Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myelodysplastic Syndrome Market

• 24.1. USA Myelodysplastic Syndrome Market Overview
• 24.2. USA Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myelodysplastic Syndrome Market

• 25.1. Canada Myelodysplastic Syndrome Market Overview
• 25.2. Canada Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myelodysplastic Syndrome Market

• 26.1. South America Myelodysplastic Syndrome Market Overview
• 26.2. South America Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myelodysplastic Syndrome Market

• 27.1. Brazil Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myelodysplastic Syndrome Market

• 28.1. Middle East Myelodysplastic Syndrome Market Overview
• 28.2. Middle East Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myelodysplastic Syndrome Market

• 29.1. Africa Myelodysplastic Syndrome Market Overview
• 29.2. Africa Myelodysplastic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myelodysplastic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myelodysplastic Syndrome Market Competitive Landscape And Company Profiles

• 30.1. Myelodysplastic Syndrome Market Competitive Landscape
• 30.2. Myelodysplastic Syndrome Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Myelodysplastic Syndrome Market Other Major And Innovative Companies

• 31.1. Merck & Co.
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca Plc.
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Medtronic Plc
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Otsuka Pharmaceutical Co. Ltd.
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Astellas Pharma Inc.
• 31.13. Daiichi Sankyo Company Ltd.
• 31.14. Jazz Pharmaceuticals
• 31.15. Dr. Reddy's Laboratories Ltd.

32. Global Myelodysplastic Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myelodysplastic Syndrome Market

34. Recent Developments In The Myelodysplastic Syndrome Market

35. Myelodysplastic Syndrome Market High Potential Countries, Segments and Strategies

• 35.1 Myelodysplastic Syndrome Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myelodysplastic Syndrome Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myelodysplastic Syndrome Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer